6 May 2024 in Journal of Voice
NBNathalie Henrich Bernardoni
Nathalie Henrich Bernardoni
This study aims to explore the effects of thyroidectomy-a surgical intervention involving the removal of the thyroid gland-on voice quality, as represented by acoustic and electroglottographic measures. Given the thyroid gland's proximity to the inferior and superior laryngeal nerves, thyroidectomy carries a potential risk of affecting vocal function. While earlier studies have documented effects on the voice range, few studies have looked at voice quality after thyroidectomy. Since voice quality effects could manifest in many ways, that a priori are unknown, we wish to apply an exploratory approach that collects many data points from several metrics. A voice-mapping analysis paradigm was applied retrospectively on a corpus of spoken and sung sentences produced by patients who had thyroid surgery. Voice quality changes were assessed objectively for 57 patients prior to surgery and 2months after surgery, by making comparative voice maps, pre- and post-intervention, of six acoustic and electroglottographic (EGG) metrics. After thyroidectomy, statistically significant changes consistent with a worsening of voice quality were observed in most metrics. For all individual metrics, however, the effect sizes were too small to be clinically relevant. Statistical clustering of the metrics helped to clarify the nature of these changes. While partial thyroidectomy demonstrated greater uniformity than did total thyroidectomy, the type of perioperative damage had no discernible impact on voice quality. Changes in voice quality after thyroidectomy were related mostly to increased phonatory instability in both the acoustic and EGG metrics. Clustered voice metrics exhibited a higher correlation to voice complaints than did individual voice metrics.
8 March 2019 in Surgical and Radiologic Anatomy
14 November 2023 in The Journal of Clinical Endocrinology & Metabolism
Objective When transsphenoidal surgery (TSS) doesn’t cure Cushing’s disease (CD), four treatments are available: drug treatment (DT); second TSS (2nd TSS); bilateral adrenalectomy (BA); pituitary radiotherapy (PR). DT is attractive but supposes long-term continuation, which we aimed to evaluate. Design and Methods Retrospective study, in a center prioritizing 2nd TSS, of 36 patients, including 19 with TSS failure and 17 with recurrence, out of 119 patients with CD treated by a 1st TSS, average follow-up 6.1 years (IC95 5.27-6.91). Control was defined as normalisation of urinary free cortisol (UFC), final treatment (FT) as the treatment allowing control at last follow-up. We also analysed discontinuation rates of DT in published CD prospective clinical trials. Results Control was achieved in 33/36 patients (92%). DT was initiated in 29/36 patients (81%), allowing at least one normal UFC in 23/29 patients (79%), but was discontinued before last follow-up in 18/29 patients (62%). DT was FT in 11/29 patients (38%), all treated with cortisol synthesis inhibitors. 2nd TSS was FT in 8/16 (50%); BA in 14/14 (100%); PR in in 0/5. In published trials discontinuation of DT was 11-51% at 1 year and 32-74% before 5 years. Conclusion DT allowed at least one normal UFC in 23/29 patients (79%) but obtained long-term control in only 11/29 (38%), as discontinuation rate was high, although similar to published data. Interestingly, a successful 2nd TSS was the cause for discontinuing efficient and well tolerated DT in 5 patients. Further studies will show whether different strategies with cortisol synthesis inhibitors may allow for a lower discontinuation rate in patients not candidates for a 2nd TSS, so that BA may be avoided in these patients.
12 January 2022 in Anatomical Sciences Education
15 July 2021 in General Thoracic and Cardiovascular Surgery
16 January 2024 in The Journal of Clinical Endocrinology & Metabolism
Dear Editor, We thank Dr. Piazzola and Prof. Castinetti for their insightful comments ( 1) on our study on long-term treatment of 36 patients with Cushing disease (CD) not cured by transsphenoidal surgery (TSS) ( 2). Drug treatment (DT) was initiated in 29/36 patients but it proved a long-term efficient treatment in only 38% (11/29). We agree that these results are provocative: How can we explain that DT was discontinued so frequently? First the authors are right to note that we gave priority to curative treatment, especially second TSS (2nd TSS), successful in 8/16 patients. These 8 patients included 5 in whom DT allowed a normal Urinary Free Cortisol, so that if we had not performed 2nd TSS in these 5 patients, the rate of patients with long-term control by DT would have been 55% (16/29). We think however that 2nd TSS was beneficial to these 5 patients: first, 2 were women with a short- or long-term aim of pregnancy, impossible with DT other than cabergoline, to which they were not sensitive; secondly the follow-up of all 5 patients, which is detailed in the manuscript favors the hypothesis that successful 2nd TSS may provide better clinical outcomes than DT, as already suggested by the HairCush study ( 3). <!-- /foreach in Model.Sections -->